Indications for plasma exchange in systemic lupus erythematosus in 2005

Lupus

Volumn 14, Issue 11, 2005, Pages 871-877

  Pagnoux, Christian ^a   Korach, J M ^b   Guillevin, L ^a  

^a Université René Descartes ^*  (France)

^b General Hospital   (France)

Author keywords

Immunoadsorption; Plasma exchange; Plasmapheresis; Systemic lupus erythematosus

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DISEASE SEVERITY; HUMAN; HYPERVISCOSITY SYNDROME; IMMUNOADSORPTION; KIDNEY DISEASE; LUNG HEMORRHAGE; MEDICAL TECHNOLOGY; NEUROPSYCHIATRY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERMINAL DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMA EXCHANGE;

EID: 28444438854     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2174rr     Document Type: Review

References (100)

1. Moriconi L, Ferri C, Fanara G et al. Plasma exchange in the treatment of lupus nephritis. Int J Artif Organs 1983; 6(Suppl. 1): 35-38.
2. Jones JV, Robinson MF, Parciany RK, Layfer LF, McLeod B. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthritis Rheum 1981; 24: 1113-1120.
3. Rifle G, Mousson C, Tanter Y. Hemapheresis in systemic lupus erythematosus. Clin Exp Rheumatol 1990; 8(Suppl. 5): 51-55.
4. Clark WF, Lindsay RM, Cattran DC, Chodirker WB, Barnes CC, Linton AL. Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study. Can Med Assoc J 1981; 125: 171-174.
5. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326: 1373-1379.
6. Lewis EJ. Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group. J Clin Apheresis 1992; 7: 153.
7. Derksen RH, Hene RJ, Kallenberg CG, Valentijn RM, Kater L. Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 1988; 33: 168-177.
8. Wei N, Klippel JH, Huston DP et al. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1: 17-22.
9. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
10. Jones JV, Cumming RH, Bucknall RC, Asplin CM. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976; 1: 709-711.
11. Gayraud M, Guillevin L, Sobel A. Traitement du lupus systémique sévère par corticoïdes, immunosuppresseurs et échanges plasmatiques. Sem Hôp Paris 1986; 62: 453-458.
12. Lockwood CM, Pussell B, Wilson CB, Peters DK. Plasma exchange in nephritis. Adv Nephrol Necker Hosp 1979; 8: 383-418.
13. Kater L, Derksen RH, Houwert DA et al. Effect of plasmapheresis in active systemic lupus erythematosus. Neth J Med 1981; 24: 209-216.
14. Hamburger MI. A long-term study of plasmapheresis and cyclophosphamide in systemic lupus erythematosus [abstract]. J Clin Apheresis 1984; 2: 143.
15. Clark WF, Lindsay RM, Ulan RA, Cordy PE, Linton AL. Chronic plasma exchange therapy in SLE nephritis. Clin Nephrol 1981; 16: 20-23.
16. Habersetzer R, Samtleben W, Blumenstein M, Gurland HJ. Plasma exchange in systemic lupus erythematosus. Int J Artif Organs 1983; 6(Suppl. 1): 39-41.
17. Schena FP, Manno C, Carabellese S, Dimonte D, Paglionico N, Cazzato L. Plasma exchange in systemic lupus erythematosus. Int J Artif Organs 1983; 6(Suppl. 1): 29-33.
18. Parry HF, Moran CJ, Snaith ML et al. Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 1981; 40: 224-228.
19. Schlansky R, De Horatius RJ, Pincus T, Tung KS. Plasmapheresis in systemic lupus erythematosus: a cautionary note. Arthritis Rheum 1981; 24: 49-53.
20. Wallace DJ. Plasmapheresis for lupus nephritis [letter]. N Engl J Med 1992; 327: 1029.
21. Lewis EJ. Plasmapheresis for lupus nephritis [letter]. N Engl J Med 1992; 327: 1029-1030.
22. Schroeder JO, Euler HH, Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987; 107: 344-346.
23. Euler HH, Schroeder JO for the Lupus Plasmapheresis Study Group. Plasmapheresis for lupus nephritis [letter]. N Engl J Med 1992; 327: 1028.
24. Clark WF, Dau PC, Euler HH et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). J Clin Apheresis 1991; 6: 40-47.
25. Euler HH, Schroeder JO. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus Sci 1992; 13: 167-184.
26. Sturgill BC, Worzniak MJ. Stimulation of proliferation of 19S antibody-forming cells in the spleens of immunized guinea pigs after exchange transfusion. Nature 1970; 228: 1304-1305.
27. Schroeder JO, Schwab U, Zeuner R, Fastenrath S, Euler HH. Plasmapheresis and subsequent pulse cyclophosphamide in severe SLE: preliminary results of the LPSG Trial [abstract]. Arthritis Rheum 1997; 40(Suppl): S325.
28. Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Ann Méd Interne (Paris) 1994; 145: 296-302.
29. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-1794.
30. Johannessen A, Gutteberg T, Husby G. Plasma exchange in the treatment of severe, childhood onset systemic lupus erythematosus. Acta Paediatr Scand 1982; 71: 347-350.
31. Jordan SC, Ho W, Ettenger R, Salusky IB, Fine RN. Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. Pediatr Nephrol 1987; 1: 276-280.
32. Wright EC, Tullus K, Dillon MJ. Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol 2004; 19: 1108-1114.
33. Korach JM, Bussel H, Annane D, Gajdos P. 1991 registry of the French Society of Hemapheresis (SFH): preliminary results for the first year of the on-line computer access file. The Registry Study Group. Transfus Sci 1993; 14: 281-285.
34. Korach JM, Petitpas D, Poiron L, Vincent N, Berger PH, Chillet P. 14 years of therapeutic plasma exchange in France. Transfus Apheresis Sci 2001; 25: 73-77.
35. Stegmayr B, Korach JM, Norda R, Rock G, Fadel F. Is there a need for a national or a global apheresis registry? Transfus Apheresis Sci 2003; 29: 179-185.
36. Norda R, Stegmayr BG. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish Apheresis Study Group. Transfus Apheresis Sci 2001; 24: 49-55.
37. Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian Aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993; 23: 646-651.
38. Hochberg MC. Prevalence of systemic lupus erythematosus in England and Wales, 1981-2. Ann Rheum Dis 1987; 46: 664-666.
39. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41: 414-420.
40. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991; 114: 924-929.
41. Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group. Intensive Care Med 1998; 24: 452-458.
42. Raj R, Murin S, Matthay RA, Wiedemann HP. Systemic lupus erythematosus in the intensive care unit. Crit Care Clin 2002; 18:781-803.
43. Wallace DJ. Apheresis for lupus erythematosus: state of the art. Lupus 2001; 10: 193-196.
44. O'Callaghan CA. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol 2004; 18: 411-427.
45. Mistry-Burchardi N, Schonermarck U, Samtleben W. Apheresis in lupus nephritis. Ther Apher 2001; 5: 161-170.
46. Wallace DJ, Goldfinger D, Pepkowitz SH et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 1998; 13: 163-166.
47. Harada T, Miyazaki M, Ozono Y et al. Therapeutic apheresis for renal diseases. Ther Apher 1998; 2: 193-198.
48. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-763.
49. Guillevin L, Pagnoux C. Indications of plasma exchange for systemic vasculitides. Ther Apher Dial 2003; 7: 155-160.
50. Mintz G, Galindo LF, Fernandez-Diez J, Jimenez FJ, Robles-Saavedra E, Enriquez-Casillas RD. Acute massive pulmonary hemorrhage in systemic lupus erythematosus. J Rheumatol 1978; 5: 39-50.
51. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76: 192-202.
52. Erickson RW, Franklin WA, Emlen W Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994; 24: 114-123.
53. Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci 1994; 15: 283-288.
54. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134: 1033-1042.
55. Simpson IJ, Doak PB, Williams LC et al. Plasma exchange in Goodpasture's syndrome. Am J Nephrol 1982; 2: 301-311.
56. Unterweger B, Klein G, Fleischhacker WW. Plasma exchange for cerebral lupus erythematosus. Biol Psychiatry 1988; 24: 946-947.
57. Guthrie JA, Turney JH. Plasma exchange for cerebral lupus erythematosus. Lancet 1987; 1: 506-507.
58. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
59. Evans DT, Giles M, Home DJ, d'Apice AJ, Riglar A, Toh BH. Cerebral lupus erythematosus responding to plasmaphaeresis. Postgrad Med J 1981; 57: 247-251.
60. Perisse D, Amoura Z, Cohen D et al Case study: effectiveness of plasma exchange in an adolescent with systemic lupus erythematosus and catatonia. J Am Acad Child Adolesc Psychiatry 2003; 42: 497-499.
61. Slovick DI. Treatment of acute myelopathy in systemic lupus erythematosus with plasma exchange and immunosuppression. J Neurol Neurosurg Psychiatry 1986; 49: 103-105.
62. Espinosa G, Bucciarelli S, Cervera R et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-736.
63. Bray VJ, West SG, Kristo DA. Simultaneous presentation of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J 1994; 87: 827-830.
64. Levine S, Shearn MA. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch Intern Med 1964; 113: 826-836.
65. Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999; 42: 2346-2355.
66. Porta C, Bobbio-Pallavicini E, Centurioni R, Caporali R, Montecucco CM. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Italian Cooperative Group for TTP. J Rheumatol 1993; 20: 1625-1626.
67. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28: 1-19.
68. Shehata N, Kouroukis C, Kelton JG. A review of randomized controlled trials using therapeutic apheresis. Transfus Med Rev 2002; 16: 200-229.
69. Clark WF, Rock GA, Buskard N et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-462.
70. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol 1992; 19: 1474-1478.
71. Zhang W, You X, Dong Y. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: report of three cases. Chin Med J (Engl) 2004; 117: 637-640.
72. Bosly A, Keating MJ, Stasi R, Bradstock K. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Anticancer Drugs 2002; 13(Suppl. 2): S25-33.
73. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189-195.
74. Merrill JT. Rituximab in antiphospholipid syndrome. Curr Rheumatol Rep 2003; 5: 381-382.
75. Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
76. Cervera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113-124.
77. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 355-377.
78. Roberts G, Gordon MM, Porter D, Jardine AG, Gibson IW. Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: successful outcome using plasma exchange therapy. Lupus 2003; 12: 251-257.
79. Neuwelt CM, Daikh DI, Linfoot JA et al. Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum 1997; 40: 1534-1539.
80. Koschmieder S, Miesbach W, Fauth F, Bojunga J, Scharrer I, Brodt HR. Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coagul Fibrinolysis 2003; 14: 395-399.
81. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48: 3320-3327.
82. Fukasawa T, Arai T, Naruse T, Maekawa T Hyperviscosity syndrome in a patient with systemic lupus erythematosus. Am J Med Sci 1977; 273: 329-334.
83. Jara LJ, Capin NR, Lavalle C. Hyperviscosity syndrome as the initial manifestation of systemic lupus erythematosus. J Rheumatol 1989; 16: 225-230.
84. Garcia-Carrasco M, Ramos-Casals M, Cervera R et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001; 30: 366-373.
85. Howard TW, Iannini MJ, Burge JJ, Davis JS. Rheumatoid factor, cryoglobulinemia, anti-DNA, and renal disease in patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 826-830.
86. Berkman EM, Orlin JB. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980; 20: 171-178.
87. van der Leij JN, Visser GH, Bink-Boelkens MT, Meilof JF, Kallenberg CG. Successful outcome of pregnancy after treatment of maternal anti-Ro (SSA) antibodies with immunosuppressive therapy and plasmapheresis. Prenat Diagn 1994; 14: 1003-1007.
88. Maeshima E, Yamada Y, Kodama N, Mune M, Yukawa S. Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Scand J Rheumatol 1999; 28: 54-57.
89. Buyon J, Roubey R, Swersky S et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988; 15: 1104-1108.
90. Miyakata S, Takeuchi K, Yamaji K, Kanai Y, Tsuda H, Takasaki Y. Therapeutic plasmapheresis for the prevention of congenital complete heart block associated with anti-SS-A/Ro antibody and anti-SS-B/La antibody [abstract] [in Japanese]. Ryumachi 2001; 41: 726-735.
91. Siami GA, Siami FS. The current status of therapeutic apheresis devices in the United States. Int J Artif Organs 2002; 25: 499-502.
92. Graninger M, Schmaldienst S, Derfler K, Graninger WB. Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 2002; 29: 26-29.
93. Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001; 44: 1962-1963.
94. Braun N, Erley C, Klein R, Kotter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000; 15: 1367-1372.
95. El-Habib R, Laville M, Traeger J. Specific adsorption of circulating antibodies by extracorporeal plasma perfusions over antigen-coated collagen flat-membranes: applications to systemic lupus erythematosus. J Clin Lab Immunol 1984; 15: 111-117.
96. Hashimoto H, Tsuda H, Kanai Y et al. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran-sulfate columns in patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 545-551.
97. Suzuki K, Hara M, Ishizuka T et al. Continuous anti-dsDNA antibody apheresis in systemic lupus erythematosus. Lancet 1990; 336: 753-754.
98. Braun N, Junger M, Klein R, Gutenberger S, Guagnin M, Risler T. Dextran-sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Ther Apher 2002; 6: 471-477.
99. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
100. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798-800.